New drug trial offers hope for tough blood cancers
NCT ID NCT07107126
Summary
This early-stage study is testing a new drug called RPT1G in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have returned or not responded to standard treatments. The main goals are to find out if the drug is safe, what side effects it causes, and to determine the best dose for future studies. Researchers will enroll about 24 patients to carefully monitor how their bodies handle the medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.